Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy

Detalles Bibliográficos
Autores principales: Brochez, Lieve, Kruse, Vibeke, Schadendorf, Dirk, Muller, Alexander J., Prendergast, George C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686161/
https://www.ncbi.nlm.nih.gov/pubmed/34938297
http://dx.doi.org/10.3389/fimmu.2021.789473
_version_ 1784617963363500032
author Brochez, Lieve
Kruse, Vibeke
Schadendorf, Dirk
Muller, Alexander J.
Prendergast, George C.
author_facet Brochez, Lieve
Kruse, Vibeke
Schadendorf, Dirk
Muller, Alexander J.
Prendergast, George C.
author_sort Brochez, Lieve
collection PubMed
description
format Online
Article
Text
id pubmed-8686161
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86861612021-12-21 Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy Brochez, Lieve Kruse, Vibeke Schadendorf, Dirk Muller, Alexander J. Prendergast, George C. Front Immunol Immunology Frontiers Media S.A. 2021-12-06 /pmc/articles/PMC8686161/ /pubmed/34938297 http://dx.doi.org/10.3389/fimmu.2021.789473 Text en Copyright © 2021 Brochez, Kruse, Schadendorf, Muller and Prendergast https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Brochez, Lieve
Kruse, Vibeke
Schadendorf, Dirk
Muller, Alexander J.
Prendergast, George C.
Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy
title Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy
title_full Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy
title_fullStr Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy
title_full_unstemmed Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy
title_short Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy
title_sort editorial: targeting indoleamine 2,3-dioxygenases and tryptophan dioxygenase for cancer immunotherapy
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686161/
https://www.ncbi.nlm.nih.gov/pubmed/34938297
http://dx.doi.org/10.3389/fimmu.2021.789473
work_keys_str_mv AT brochezlieve editorialtargetingindoleamine23dioxygenasesandtryptophandioxygenaseforcancerimmunotherapy
AT krusevibeke editorialtargetingindoleamine23dioxygenasesandtryptophandioxygenaseforcancerimmunotherapy
AT schadendorfdirk editorialtargetingindoleamine23dioxygenasesandtryptophandioxygenaseforcancerimmunotherapy
AT mulleralexanderj editorialtargetingindoleamine23dioxygenasesandtryptophandioxygenaseforcancerimmunotherapy
AT prendergastgeorgec editorialtargetingindoleamine23dioxygenasesandtryptophandioxygenaseforcancerimmunotherapy

Ejemplares similares